Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Long-Term Debt Repayments (2022 - 2024)

Coeptis Therapeutics Holdings has reported Long-Term Debt Repayments over the past 3 years, most recently at $63469.0 for Q4 2024.

  • Quarterly results put Long-Term Debt Repayments at $63469.0 for Q4 2024, down 81.87% from a year ago — trailing twelve months through Dec 2024 was $700970.0 (down 17.53% YoY), and the annual figure for FY2024 was $650969.0, down 46.86%.
  • Long-Term Debt Repayments for Q4 2024 was $63469.0 at Coeptis Therapeutics Holdings, down from $287500.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for COEPW hit a ceiling of $500000.0 in Q4 2022 and a floor of $50000.0 in Q3 2022.
  • Median Long-Term Debt Repayments over the past 3 years was $268750.0 (2022), compared with a mean of $250161.7.
  • Biggest five-year swings in Long-Term Debt Repayments: dropped 30.0% in 2023 and later plummeted 81.87% in 2024.
  • Coeptis Therapeutics Holdings' Long-Term Debt Repayments stood at $500000.0 in 2022, then dropped by 30.0% to $350001.0 in 2023, then plummeted by 81.87% to $63469.0 in 2024.
  • The last three reported values for Long-Term Debt Repayments were $63469.0 (Q4 2024), $287500.0 (Q1 2024), and $350001.0 (Q4 2023) per Business Quant data.